Moderately to Severely Active Ulcerative Colitis
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00051 | Adalimumab | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
| DB14766 | Etrasimod | An S1P receptors modulator used to treat moderate to severely active ulcerative colitis in adults |
| DB14845 | Filgotinib | A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. |
| DB00065 | Infliximab | A monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
| DB14910 | Mirikizumab | An anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis. |
| DB12612 | Ozanimod | A sphingosine 1-phosphate receptor modulator being studied to treat Multiple Sclerosis (MS) and inflammatory bowel disease (IBD). |
| DB15091 | Upadacitinib | An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. |
| DB09033 | Vedolizumab | An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. |